TOKYO, May 28, 2018 - (JCN Newswire) - Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet" (nonproprietary name: elobixibat hydrate; development code: AJG533, hereinafter "elobixibat"), a bile acid transporter inhibitor launched in Japan on April 19, 2018, will be given at Digestive Disease Week (DDW) 2018, June 2-5 in Washington D.C., USA.
Elobixibat is a once-daily, orally available constipation treatment1) with a novel action mechanism. EA Pharma in-licensed this product from Albireo AB (Sweden). Elobixibat inhibits the bile acid transporter that regulates reabsorption of bile acids thereby increasing the flow of bile acids to the colon. The dual action of moisture secretion and bowel movement promotion by bile acids can facilitate defecation. Elobixibat is the world's first pharmaceutical product approved for marketing with the above action mechanism. At DDW2018, safety results obtained from a PIII clinical study and a long-term dosing study will be presented.
Elobixibat was jointly developed by EA Pharma and Mochida. EA Pharma and Mochida distribute elobixibat under the same brand name "GOOFICE 5mg Tablet", respectively, in Japan. EA Pharma and Eisai jointly provide proper use information of "GOOFICE 5mg Tablet" under a co-promotion agreement.
EA Pharma, Eisai and Mochida strive to make a further contribution to improve QOL for patients with chronic constipation through maximization of product value of "GOOFICE 5mg Tablet".
About EA Pharma Co., Ltd.
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 years' history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma is a gastrointestinal specialty pharma with a full value chain covering R&D, logistics and sales & marketing.
For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/en/
About Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. has been committed to research and development of innovative pharmaceutical products since its establishment thereby providing distinctive medicines to the medical field. Currently, the core pharmaceutical business focuses resources on the targeted areas of cardiovascular, obstetrics and gynecology, dermatology, psychiatry and gastroenterology, while also providing medicine for intractable disease as well as generics including biosimilars, to meet medical needs.
For more information on Mochida Pharmaceutical Co., Ltd., please see
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit https://www.eisai.com.
EA Pharma Co., Ltd.
Corporate Planning Dept.
Mochida Pharmaceutical Co., Ltd.
Public Relations Department,
Eisai Co., Ltd.
May 28, 2018 16:06 HKT/SGT
Eisai (TSE: 4523)
Topic: Press release summary
Sectors: BioTech, HealthCare
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.